tbuckley/cabot-search huggingface dataset:
SAT0633-HPR Social Support May Be Important for Improving Patient Satisfaction and Health Status in Patients with Rheumatoid Arthritis Treated with Biologics
Authors: M. Fusama, K. Yukioka, T. Kuroiwa, C. Yukioka, M. Inoue, K. Higashi, A. Ogata, N. Murata, T. Kuritani, K. Maeda, H. Sano, M. Yukioka, H. Nakahara
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The clinical benefits of biologics to patients with rheumatoid arthritis (RA) have been demonstrated in various clinical trials. However, patient satisfaction in patients treated with biologics is not well evaluated. <h3>Objectives</h3> We evaluated patient satisfaction and health status in patients with RA treated with biologics. <h3>Methods</h3> The patients with RA who were planning to be treated with IL-6 inhibitor (tocilizumab; TCZ) (IL-6 group) and TNF inhibitor (adalimumab: ADA, infliximab; IFX, etanercept; ETN) (TNF group) were enrolled. Disease activity was evaluated using swollen joint counts (SJC), tender joint counts (TJC) and patient global assessment (PGA), and Clinical Disease Activity Index (CDAI). Patient satisfaction was evaluated utilizing patient satisfaction scores of the Arthritis Impact Measurement Scale 2 (AIMS-2). Satisfaction was measured before and after 6-months of treatment with each of the biologics, and the results were compared. Statistical analysis was performed utilizing Wilcoxon rank-sum test and t-test. <h3>Results</h3> Patients with RA (n=85) were evaluated in this study. 48 patients were treated with TCZ, and 47 patients were treated with anti-TNF agents (ADA: 17, IFX:17, ETN:13).Patients characteristics were as follows as follows: mean±SD of age (55.6±11.9 years old) and duration (7.29±8.83 years), male/female (16/79). Both at baseline and at 6 months after treatment, there was no statistically significant differences in SJC, TJC, PGA, EGA and CDAI between TCZ group and TNF group. All these evaluations showed statistically significant improvement after 6 months of treatment in each group.As for health status, all 5 components of AIMS-2 showed statistically significant improvement at 6 months compared to the baseline in TNF groups. In IL-6 group, "physical", "symptom", "affect" and "role" improved significantly at 6 months (p&lt;0.001, for all items), while "social interaction" did not statistically improve compared to the baseline (p=0.114). Out of 12 satisfaction scores, all scores except "understanding and support for patients9 problems by families or friends" (p=0.133) showed statistically significant improvement with 6 months of treatment in TNF group, while all 12 scores improved significantly at 6 months in IL-6 groups. <h3>Conclusions</h3> Patient satisfaction and health status except social interaction were improved by TNF inhibitor or IL-6 inhibitor. To solve the problems related to social function, understandings and social support for patients by health professionals may be required. <h3>Disclosure of Interest</h3> None declared
Impact of Early Lymphocyte Recovery On Transplant Outcome After Cord Blood Transplantation.
Authors: Sara K Tedeschi, Brian Engelhardt, Waleed Khalaf, Janice Tracy, Jennifer Domm, Wichai Chinratanalab, Adetola A. Kassim, Stacey Goodman, John P. Greer, Friedrich Schuening, Madan Jagasia, Haydar Frangoul, Bipin N. Savani
Journal: Blood (2009)
Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients
Authors: Stephen M. Ansell, Matthew J Maurer, Steven C. Ziesmer, Susan L Slager, Thomas M. Habermann, Brian K Link, Thomas E. Witzig, David James Inwards, Joseph P. Colgan, James R Cerhan, Anne J. Novak
Journal: Blood (2011)
NIR‐Mediated Nanohybrids of Upconversion Nanophosphors and Fluorescent Conjugated Polymers for High‐Efficiency Antibacterial Performance Based on Fluorescence Resonance Energy Transfer
Authors: Junting Li, Qi Zhao, Feng Shi, Chenghui Liu, Yanli Tang
Journal: Advanced Healthcare Materials (2016)

A novel nanohybrid comprised of upconversion nanophosphors (UCNPs) and fluorescent conjugated polymers (PFVCN) is rationally fabricated. The new UCNP/PFVCN nanohybrids combine the excellent antibacterial ability of PFVCN and the near IR (NIR) absorbing property of UCNPs, which allows for NIR-mediated antibacterial through the effective fluorescence resonance energy transfer from UCNPs to PFVCN accompanied with generation of reactive oxygen species to kill bacteria. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
THU0521 Prevalence of Gout and ULT Treatment in Western Sweden – A Register Study
Authors: M.I. Dehlin, P. Drivelegka, V. Sigurdardottir, A. Svärd, L. Jacobsson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout is the most common inflammatory arthritic disease worldwide. The prevalence varies due to cultural, ethnical and genetic differences in populations, which emphasizes the need for national/regional data on occurrence. There are major insights in the pathogenesis and effective treatments have been available for decades. Despite this several earlier reports state sub-optimal treatment with urate lowering therapy (ULT) of this common and severe disease. Contemporary data on whether this has improved recently are overall few and completely lacking from the Nordic countries. <h3>Objectives</h3> In the present study we measured the prevalence of gout in western Sweden and the proportion thereof treated with ULT. <h3>Methods</h3> We identified all individuals with one or more ICD-10 diagnosis of gout (M10, M14) in the Western Swedish Health Care Region (WSHCR), Sweden, 2002-01-01 to 2012-12-31 through VEGA, a diagnosis register entailing all visits to physicians in primary and secondary care and hospitalizations in the region with diagnosis according to the Swedish version of ICD-10. WSHCR has 1 600 000 inhabitants, roughly 20% of the population of Sweden and is representative for the country as a whole with regard to demographics and health status. All cases were linked to Statistics Sweden (for death and possible emigration before Dec 2012) and the National Drug Prescription Register (for dispensation of ULT prescriptions during 2012). The point prevalence of gout Dec 2012 was calculated using the number of people aged 20 and above fulfilling our case definitions for gout who were alive and living in WSHCR 2012-12-31 as the numerator and the total population aged 20 and above of WSHCR by 2012–12–31 as the denominator. Dispensation of ULT prescriptions during 2012 were identified for allopurinol, febuxostat and probenecid. The presence of ≥1 dispensation was regarded as ULT treatment in 2012. <h3>Results</h3> The prevalence of gout in the Swedish population aged 20 years and above was 1,7% overall and increased with age and male sex (Fig 1), and was more than 3% in males above 50 years of age. Only 43% of the patients received treatment with ULT in 2012, almost exclusively allopurinol (99%). Of these 43%, the majority (59%) received a dose of only 100 mg allopurinol daily. <h3>Conclusions</h3> Gout is the most common inflammatory arthritic disease in Sweden with an overall prevalence of 1.7%. Treatment with ULT is still in 2012 insufficient with low a low proportion being treated and those treated receiving low doses. <h3>Disclosure of Interest</h3> None declared
INK4 Locus Deletion in Childhood Acute Lymphoblastic Leukemia (ChALL)-a Preliminary Clinical Evaluation
Authors: Anna Paisiou, Stefanos I Papadhimitriou, Nikolaos Tsagarakis, Vassilios Papadakis, Nektaria Kentrou, Georgios Paterakis, Agapi Parcharidou, Georgios Androutsos, Konstantinos Tsitsikas, Ioannis Kostopoulos, Dimitris Pavlidis, Maria Georgaki, Sophia Polychronopoulou
Journal: Blood (2008)
Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)
Authors: Anna Fink, Natali Pflug, Raymonde Busch, Gunter R. Fingerle-Rowson, Barbara Eichhorst, Clemens-Martin Wendtner, Dirk Winkler, Andreas Buehler, Myriam Mendila, Michael Wenger, Hartmut Dohner, Stephan Stilgenbauer, Michael Hallek, Kirsten Fischer
Journal: Blood (2010)
CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.
Authors: Carolina Terragna, Sandra Durante, Annalisa Astolfi, Francesca Palandri, Fausto Castagnetti, Gianantonio Rosti, Nicoletta Testoni, Simona Luatti, Ilaria Iacobucci, Thea Kalebic, Simona Soverini, Marilina Amabile, Angela Poerio, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2009)
PWE-116 Detection of Colorectal Cancer from Urinary Volatile Organic Compounds Using a New Chromatograph/Electronic-Nose Instrument – Wolf System
Authors: E Westenbrink, N O’Connell, C Bailey, C Nwokolo, K Bardhan, R Arasaradnam, J Covington
Journal: Gut (2016)

<h3>Introduction</h3> Colorectal cancer (CRC) remains one of the leading causes of cancer-related death in Europe and the USA. The gold standard diagnostic test of colonoscopy is highly invasive, expensive and has an associated morbidity. The current non-invasive option for CRC screening includes Faecal Immunochemical Testing (FIT) for haemoglobin, which shows a specificity of 87–96%, but has a wide variation in potential sensitivity (66–88%). One non-invasive method that is gaining interest for the diagnosis of a variety of cancers measures the volatiles/gases that emanate from human biological media. <h3>Methods</h3> Urine samples were collected from 26 CRC and 23 controls (Irritable bowel syndrome patients; IBS) and stored at -80<sup> o</sup>C. 5 mL aliquots were heated to 40<sup>o</sup>C for 5 minutes to develop sufficient headspace. The WOLF 3.1 gas chromatograph/electronic nose instrument, developed at Warwick University, was used to analyse the resultant headspace. The analysis method took a total of 25 minutes for each sample, with an air purge in between to avoid cross-contamination. Statistical evaluation by Linear Discriminant Analysis (LDA) was tested by repeated trials of single unknown sample by re-introduction and re-classification by a K-Nearest-Neighbour technique. <h3>Results</h3> Figure 1 below shows the 2 group LDA classification of CRC and IBS samples using response time slices of 100 seconds and extraction of two response features from each. There is distinction between the disease groups, with no overlap seen in any of the samples in this population (P &lt; 0.0001). The sensitivity and specificity of distinguishing CRC from IBS controls from KNN re-classification were 92% and 77% respectively. <h3>Conclusion</h3> This pilot study affirms the utility of a custom made WOLF 3.1 gas chromatograph-electronic nose instrument to detect CRC using urine samples. Further validation in a larger sample set is underway but holds promise for a simple, economical tool in CRC detection. <h3>Disclosure of Interest</h3> None Declared
Quantification of Type, Timing, and Extent of Cell Body and Nucleus Deformations Caused by the Dimensions and Hydrophilicity of Square Prism Micropillars
Authors: Onur Hasturk, Abdullah Sivas, Bulent Karasozen, Utkan Demirci, Nesrin Hasirci, Vasif Hasirci
Journal: Advanced Healthcare Materials (2016)

Novel digital analysis strategies are developed for the quantification of changes in the cytoskeletal and nuclear morphologies of mesenchymal stem cells cultured on micropillars. Severe deformations of nucleus and distinct conformational changes of cell body ranging from extensive elongation to branching are visualized and quantified. These deformations are caused mainly by the dimensions and hydrophilicity of the micropillars. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
The Successful Use of Archived Formalin-Fixed Paraffin-Embedded (FFPE) Material for Gene Expression Studies.
Authors: Konstantinos Lilakos, Maria K. Angelopoulou, George Georgiou, Vassilios Salpeas, Penelope Korkolopoulou, Panayiotis Panayiotidis, Gerassimos A. Pangalis
Journal: Blood (2006)
Cellular Localization Pattern of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in a Patient with Low-Grade Non-Hodgkin’s Lymphoma (NHL).
Authors: Samuel A. Jacobs, Anthony M. Harrison, Steven H. Swerdlow, Kenneth A. Foon, Norbert Avril, Nick Vidnovic, Kenneth S. McCarty, Wayne Saville
Journal: Blood (2004)
Identification of a Novel B-CLL Subset Expressing Mutated Stereotyped B-Cell Receptors with Specificity for Yeast Mannan
Authors: Robbert Hoogeboom, Kok P. van Kessel, Thera A.M. Wormhoudt, Roy J.A. Reinten, Ludo M.E. Evers, Arnon P Kater, Richard J Bende, Carel J.M. van Noesel
Journal: Blood (2011)
Integrated Genetic Profiling Of JAK2 Wildtype Chronic-Phase Myeloproliferative Neoplasms
Authors: Raajit K. Rampal, Sean M. Devlin, Jay P. Patel, Kristina M. Knapp, Minal Patel, Joel R Greenbowe, Lauren E Young, Jie He, Kai Wang, Michelle K. Nahas, Roman Yelensky, Geoff A. Otto, Doron Lipson, Philip J. Stephens, Vincent A. Miller, Ross L. Levine
Journal: Blood (2013)
AB1023 Rheuma Space: Standard Practice Aiming Clinical Excellence in Rheumatology
Authors: C. Macieira, L. Cunha-Miranda, A. Lourenço, A. Santos, J. Sousa, M. Bogas, P. Lucas, P. Laires, S. Farinha, J. Eurico da Fonseca, J. Canas da Silva
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The evaluation of the quality of medical practice and the implementation of corresponding measures to improve it are crucial steps for the development of Rheumatology in Europe. Herein we describe the implementation of a national program, Rheuma Space, aiming at quality improvement in the field of Rheumatology. <h3>Objectives</h3> To develop standards for the quality of care accepted by most of the rheumatology services in Portugal. <h3>Methods</h3> Quality indicators were obtained through a four-step RAND-modified Delphi methodology. The first step involved a literature search for international benchmarking of quality of care initiatives and indicators, followed by a pre-selection of a initial set of criteria by a task force. The final steps, aiming at defining a smaller set of criteria that could best analyze rheumatology quality of care, encompassed an online Delphi round with all Portuguese rheumatologists and a consensus meeting with a panel of invited experts representing all the Portuguese Rheumatology Departments of the National Health Service. <h3>Results</h3> A total of 412 different indicators were collected throughout the first project phase and the final set of 26 quality indicators was defined, within the three Donabedian dimensions of healthcare quality: nine "<i>structure"</i>, eleven "<i>processes"</i> and seven "<i>outcome"</i> indicators. These criteria cover eleven domains of quality of care: personnel and organizational structure, training and research, facilities, equipment and IT, budgeting and financial resources, access to care, clinical records, patient communication, multidisciplinary management, clinical outcomes, and patient and personnel satisfaction. <h3>Conclusions</h3> The 26 quality indicators set constitutes the basis for a quality management tool, which is now being implemented in all the Portuguese Rheumatology Departments of the National Health Service. Direct surveys derived from the 26 quality indicators are being applied to health professionals and patients allowing to benchmark departments and to identify strengths and weakness for future improvement. This initiative is deemed to improve the process of care for Portuguese rheumatic patients, thereby ensuring quality standards of structure and process criteria, for a patient-oriented clinical practice, favouring desirable continuous quality improvement on health outcomes. <h3>Acknowledgement</h3> Portuguese Rheumatology participating in the online Delphi and all the participants in the expert consensus meeting <h3>Disclosure of Interest</h3> None declared
Donor-Recipient Mismatches in MHC Class I Chain-Related Gene a (MICA) in Unrelated Donor (UD) Transplantation
Authors: Marcos De Lima, Morgani Rodrigues, Pedro Cano, Peter Stastny, Ping Liu, Wei Wei, Susana Pesoa, Poliana Patah, Elizabeth Shpall, Sergio Giralt, Gabriela Rondon, Martin Korbling, Leandro De Padua Silva, Richard Champlin, Marcelo Fernandez-Vina
Journal: Blood (2008)
Early Apoptotic Cells (ApoCell) As Prophylaxis of Graft-Versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantation Is Safe and Effective: 1 Year Follow-up
Authors: Dror Mevorach, Zuckerman Tzila, Arnon Nagler, Jacob M. Rowe, Reuven Or
Journal: Blood (2014)
AB0146 Self-Reactive IGE Exacerbates Interferon Responses Associated with Autoimmunity
Authors: M.A. Sanjuan, J. Henault, J. Riggs, J.L. Karnell, V. Liarski, L. Shirinian, L. Xu, K. Casey, M.A. Smith, D. Khatry, L. Clarke, R. Herbst, R. Ettinger, M. Petri, M.R. Clark, T. Mustelin, R. Kolbeck
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The discovery of Immunoglobulin E (IgE) nearly 40 years ago was a breakthrough in the field of allergy research. IgE directed against parasitic worms and allergens binds mast cells and basophils, triggering an inflammatory response that is characterized by the release of histamine and Th2 cytokines. Here we report that double-stranded DNA (dsDNA)-specific IgE autoantibodies complexed to DNA activate plasmacytoid dendritic cells (pDC), an immune cell type linked to viral defense, leading to the secretion of substantial amounts of IFN-a. Although typical IgE mediated responses are not a hallmark of systemic lupus erythematosus (SLE), IFN-a producing pDCs are a key driver for loss of immune tolerance to host DNA in SLE. We, therefore, investigated this apparent paradox and found that even the small concentrations of circulating dsDNA-specific IgE found in SLE patients greatly potentiated pDC secretion of IFN-a by triggering phagocytosis via the Fc-epsilon receptor I (FceRI) and TLR9-mediated DNA sensing in the phagolysosome. Consequently, this potent pDC signaling mechanism reduces the threshold of pDC activation, which has the potential to expand anti-DNA responses and greatly exacerbate self-inflicted damage. These findings expand the known pathogenic mechanisms of IgE mediated inflammation beyond those found in allergies and demonstrate that, in addition to recognizing exogenous allergens, IgE can also bind to autoantigens and drive an aberrant and self-destructive anti-viral response. This previously unrecognized link between IgE and the interferon pathway provides additional insights into the pathological mechanisms underlying autoimmunity and may be useful in the rational design of therapies for the treatment of diseases such as SLE. <h3>Disclosure of Interest</h3> M. Sanjuan Employee of: Medimmune, J. Henault Employee of: Medimmune, J. Riggs Employee of: Medimmune, J. Karnell Employee of: Medimmune, V. Liarski: None declared, L. Shirinian Employee of: Medimmune, L. Xu Employee of: Medimmune, K. Casey Employee of: Medimmune, M. Smith Employee of: Medimmune, D. Khatry Employee of: Medimmune, L. Clarke Employee of: Medimmune, R. Herbst Employee of: Medimmune, R. Ettinger Employee of: Medimmune, M. Petri: None declared, M. Clark: None declared, T. Mustelin Employee of: Medimmune, R. Kolbeck Employee of: Medimmune
FRI0309 Type I Interferon Activity Is Associated with Mucocutaneous but Not Musculoskeletal Disease Activity in Systemic Lupus Erythematosus:
Authors: A.A.A. Mohamed, Y. El-Sherbiny, E.M. Hensor, M.Y. Md Yusof, S.H. Goma, E.A. Abda, F.M. Abd-Allah, P. Emery, E. Vital
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> SLE is clinically and immunologically heterogeneous. Type I interferons (IFN-I) are pathogenic but expression of IFN-I stimulated genes varies. Many existing reports on clinical phenotype and IFN-I were limited by using categorical measures of IFN-I and disease activity scores that were not organ-specific. IFN-I targeted therapies are in development. <h3>Objectives</h3> To define the clinical phenotype of IFN-I mediated SLE. <h3>Methods</h3> 108 SLE patients and 20 age and sex matched healthy controls were studied. Activity was measured using BILAG-2004. PBMCs were collected for gene expression analysis using TaqMan. Relative expression of 7 interferon stimulated genes was In-transformed, normalized to healthy control and summed to derive a 7-gene IFN-I score. <h3>Results</h3> The most common activity was mucocutaneous and musculoskeletal, which were analysed in detail (Table 1). The relationship between activity and IFN-I score differed between these domains. Overall, IFN-I scores were higher in active mucocutaneous disease. Scores were more variable for BILAG B: this was explained by subtype of BILAG B disease. IFN-I score was increased in subacute and discoid forms (25.3 (16.8–32.9), n=7) compared to acute forms (18.4 (4.9–31), n=15). Score was also higher in patients with anti-Ro60. In contrast, there was no relationship between musculoskeletal disease activity and IFN-I score. Numbers of patients with renal, haematological and neuropsychiatric activity were limited but there was a trend to higher IFN-I scores with disease activity. <h3>Conclusions</h3> We identify a relationship between clinical presentation of SLE and IFN-I. High IFN-I activity is linked to anti-Ro60 and non-acute forms of skin disease. We previously reported a worse response to rituximab in this subgroup, whilst response in musculoskeletal disease was consistently good. Measurement of B cell and interferon biomarkers may therefore be important in the selection of the most appropriate targeted therapy for SLE. <h3>Disclosure of Interest</h3> None declared